(2R,3R,4R,5R,6R)-5-Acetamido-2-(acetoxymethyl)-6-(2-(2-(((benzyloxy)carbonyl)amino)ethoxy)ethoxy)tetrahydro-2H-pyran-3,4-diyl diacetate | 1261568-35-7

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2R,3R,4R,5R,6R)-5-Acetamido-2-(acetoxymethyl)-6-(2-(2-(((benzyloxy)carbonyl)amino)ethoxy)ethoxy)tetrahydro-2H-pyran-3,4-diyl diacetate
• 英文别名: [(2R,3R,4R,5R,6R)-5-acetamido-3,4-diacetyloxy-6-[2-[2-(phenylmethoxycarbonylamino)ethoxy]ethoxy]oxan-2-yl]methyl acetate
• CAS: 1261568-35-7
• 化学式: C₂₆H₃₆N₂O₁₂
• 分子量: 568.578
• InChiKey: AQFKCXLKNLSQJI-NHTNDUFYSA-N

物化性质

• 沸点：
  723.1±60.0 °C(Predicted)
• 密度：
  1.28±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  40
• 可旋转键数：
  18
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  174
• 氢给体数：
  2
• 氢受体数：
  12

安全信息

• 危险性防范说明：
  P501,P270,P264,P280,P302+P352,P337+P313,P305+P351+P338,P362+P364,P332+P313,P301+P312+P330
• 危险性描述：
  H302,H315,H319

制备方法与用途

用途

2-乙酰氨基-3,4,6-三-O-乙酰基-1-O - [(N-CBZ基氨基乙氧基)乙氧基] -2-脱氧-B-D吡喃半乳糖可用作医药中间体。

反应信息

• 作为反应物：
  描述：

  (2R,3R,4R,5R,6R)-5-Acetamido-2-(acetoxymethyl)-6-(2-(2-(((benzyloxy)carbonyl)amino)ethoxy)ethoxy)tetrahydro-2H-pyran-3,4-diyl diacetate 在 palladium-on-charcoal 甲醇 、 氢气 、 potassium carbonate 作用下， 以 甲基叔丁基醚 、 2,2,2-三氟乙醇 、 醋酸异丙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 12.5h， 生成 CDM-NAG
  参考文献：
  名称：

  [EN] CRYSTALLINE CDM-NAG AND METHODS FOR PRODUCING SAME
  [FR] CRISTAUX DE CDM-NAG ET PROCÉDÉS DE PRODUCTION ASSOCIÉS

  摘要：

  本发明提供一种晶体组合物，包括CDM-NAG。本发明还提供一种生产所述晶体组合物的方法，以及一种改进的制备NAG和CDM-NAG的方法。

  公开号：

  WO2011053614A1
• 作为产物：
  描述：

  氯甲酸苄酯 在 三氟甲磺酸三甲基硅酯 作用下， 以 2-甲基四氢呋喃 、 1,2-二氯乙烷 为溶剂， 反应 21.5h， 生成 (2R,3R,4R,5R,6R)-5-Acetamido-2-(acetoxymethyl)-6-(2-(2-(((benzyloxy)carbonyl)amino)ethoxy)ethoxy)tetrahydro-2H-pyran-3,4-diyl diacetate
  参考文献：
  名称：

  [EN] GALNAC COMPOSITIONS FOR IMPROVING SIRNA BIOAVAILABILITY
  [FR] COMPOSITIONS DE GALNAC POUR AMÉLIORER LA BIODISPONIBILITÉ D'ARNSI

  摘要：

  本文提供了一种包含GalNAc基团的组合物，可以与寡核苷酸共价结合。该寡核苷酸可以是小干扰RNA或反义寡核苷酸。本文还提供了包括将该组合物用于治疗的方法，该方法包括向受试者施用该组合物。

  公开号：

  WO2022140365A1

文献信息

• [EN] TREATMENT OF MST1R RELATED DISEASES AND DISORDERS<br/>[FR] TRAITEMENT DE MALADIES ET DE TROUBLES LIÉS À MST1R
  申请人：EMPIRICO INC

  公开号：WO2022266042A1

  公开（公告）日：2022-12-22

  Disclosed herein are compositions comprising an oligonucleotide that targetsMST1R. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated withMST1Rmutations that include providing an oligonucleotide that targetsMST1Rto a subject.

  本文公开了一种含有靶向MST1R的寡核苷酸的组合物。该寡核苷酸可能包括小干扰RNA（siRNA）或反义寡核苷酸（ASO）。本文还提供了一种治疗与MST1R突变相关疾病的方法，包括向受试者提供靶向MST1R的寡核苷酸。
• [EN] TREATMENT OF PLIN1 RELATED DISEASES AND DISORDERS<br/>[FR] TRAITEMENT DE MALADIES ET DE TROUBLES LIÉS À PLIN1
  申请人：EMPIRICO INC

  公开号：WO2022266132A1

  公开（公告）日：2022-12-22

  Disclosed herein are compositions comprising an oligonucleotide that targets PLIN1. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated withPLIN1gene mutations that include providing an oligonucleotide that targets PLIN1 in a subject.

  本文披露了一种含有靶向PLIN1的寡核苷酸的组合物。该寡核苷酸可以包括小干扰RNA（siRNA）或反义寡核苷酸（ASO）。本文还提供了一种治疗与PLIN1基因突变相关疾病的方法，该方法包括向受试者提供靶向PLIN1的寡核苷酸。
• Targeting ligands
  申请人：Arrowhead Pharmaceuticals, Inc.

  公开号：US10294474B2

  公开（公告）日：2019-05-21

  Described are novel targeting ligands that may be linked to compounds, such therapeutic compounds that are useful in directing the compounds to the in vivo target. The targeting ligands disclosed herein can serve to target expression-inhibiting oligomeric compounds, such as RNAi agents, to liver cells to modulate gene expression. The targeting ligands disclosed herein, when conjugated to a therapeutic compound, may be used in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Compositions including the targeting ligands disclosed herein when linked to expression-inhibiting oligomeric compounds are capable of mediating expression of target nucleic acid sequences in liver cells, such as hepatocytes, which may be useful in the treatment of diseases or conditions that respond to inhibition of gene expression or activity in a cell, tissue, or organism.

  本文介绍的新型靶向配体可与化合物（如治疗性化合物）连接，有助于将化合物导向体内靶点。本文公开的靶向配体可用于将表达抑制性寡聚化合物（如 RNAi 制剂）靶向肝细胞，以调节基因表达。本文公开的靶向配体与治疗化合物连接后可用于多种应用，包括治疗、诊断、靶点验证和基因组发现应用。包括本文公开的靶向配体的组合物与表达抑制性低聚化合物连接时，能够介导肝细胞（如肝细胞）中靶核酸序列的表达，这可能有助于治疗对细胞、组织或生物体中基因表达或活性的抑制有反应的疾病或病症。
• Targeting Ligands
  申请人：Arrowhead Pharmaceuticals, Inc.

  公开号：US20180064819A1

  公开（公告）日：2018-03-08

  Described are novel targeting ligands that may be linked to compounds, such therapeutic compounds that are useful in directing the compounds to the in vivo target. The targeting ligands disclosed herein can serve to target expression-inhibiting oligomeric compounds, such as RNAi agents, to liver cells to modulate gene expression. The targeting ligands disclosed herein, when conjugated to a therapeutic compound, may be used in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Compositions including the targeting ligands disclosed herein when linked to expression-inhibiting oligomeric compounds are capable of mediating expression of target nucleic acid sequences in liver cells, such as hepatocytes, which may be useful in the treatment of diseases or conditions that respond to inhibition of gene expression or activity in a cell, tissue, or organism.
• [EN] TARGETING LIGANDS<br/>[FR] LIGANDS DE CIBLAGE
  申请人：ARROWHEAD PHARMACEUTICALS INC

  公开号：WO2018044350A1

  公开（公告）日：2018-03-08

  Described are novel targeting ligands that may be linked to compounds, such therapeutic compounds that are useful in directing the compounds to the in vivo target. The targeting ligands disclosed herein can serve to target expression-inhibiting oligomeric compounds, such as RNAi agents, to liver cells to modulate gene expression. The targeting ligands disclosed herein, when conjugated to a therapeutic compound, may be used in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Compositions including the targeting ligands disclosed herein when linked to expression- inhibiting oligomeric compounds are capable of mediating expression of target nucleic acid sequences in liver cells, such as hepatocytes, which may be useful in the treatment of diseases or conditions that respond to inhibition of gene expression or activity in a cell, tissue, or organism.